Medicine:List of investigational borderline personality disorder drugs
From HandWiki
Short description: none
This is a list of investigational borderline personality disorder drugs, or drugs that are currently under development for clinical use in the treatment of borderline personality disorder (BPD) but are not yet approved.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This list was last comprehensively updated in March 2025. It is likely to become outdated with time.
Under development
Phase 3
- Quetiapine (Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator)[1]
Phase 2
- BI-1358894 – transient receptor potential channel TRPC4 and TRPC5 inhibitor[2]
- Lumateperone – atypical antipsychotic (non-selective monoamine receptor modulator)[3]
- Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen[4]
- Vafidemstat (ORY-2001) – lysine-specific demethylase 1 (LSD1; KDM1A) and monoamine oxidase B (MAO-B) inhibitor[5]
Not under development
Development discontinued
- Brexpiprazole (Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator)[6]
- Citalopram (Celexa) – selective serotonin reuptake inhibitor[7]
Formal development never or not yet started
- Other serotonergic psychedelics and entactogens (e.g., LSD, midomafetamine (MDMA))[8][9][10][11]
Clinically used drugs
Off-label drugs
- Anticonvulsants (e.g., lamotrigine, topiramate, valproic acid)[12][13][14]
- Antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs))[12][14]
- Atypical antipsychotics (e.g., aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)[15][13][14][16]
- Benzodiazepines (e.g., alprazolam, clonazepam, diazepam, lorazepam)[17][18]
- Mood stabilizers (e.g., lithium)[19]
- Omega-3 fatty acids[13]
- Sedative antihistamines (e.g., promethazine)[18]
See also
- List of investigational drugs
- List of investigational aggression drugs
References
- ↑ "Quetiapine - AstraZeneca". 6 December 2023. https://adisinsight.springer.com/drugs/800001768.
- ↑ "BI 1358894". 23 February 2024. https://adisinsight.springer.com/drugs/800049868.
- ↑ "Delving into the Latest Updates on Lumateperone Tosylate with Synapse". 28 February 2025. https://synapse.patsnap.com/drug/fc8a70896c984c36a36c2f8e40e27f08.
- ↑ "Delving into the Latest Updates on Psilocybin with Synapse". 13 February 2025. https://synapse.patsnap.com/drug/87cba64029f548f8ba9520c90896bd36.
- ↑ "Vafidemstat - Oryzon Genomics". 6 December 2024. https://adisinsight.springer.com/drugs/800045069.
- ↑ "Brexpiprazole - Lundbeck/Otsuka". 14 January 2025. https://adisinsight.springer.com/drugs/800029282.
- ↑ "Delving into the Latest Updates on Citalopram Hydrobromide with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/44027c56000f463ca0c6611346fba1a0.
- ↑ "Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis". Psychiatry Res 335. May 2024. doi:10.1016/j.psychres.2024.115886. PMID 38574699.
- ↑ "MDMA-Assisted Psychotherapy for Borderline Personality Disorder". Focus (Am Psychiatr Publ) 20 (4): 358–367. October 2022. doi:10.1176/appi.focus.20220056. PMID 37200873.
- ↑ "Exploring Serotonergic Psychedelics as a Treatment for Personality Disorders". Neuropharmacology. March 2025. doi:10.1016/j.neuropharm.2025.110413. PMID 40081794.
- ↑ "Psychedelics as a potential treatment for borderline personality disorder: A narrative review". Psychiatry Res 361. April 2026. doi:10.1016/j.psychres.2026.117152. PMID 41955843.
- ↑ 12.0 12.1 "Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies". Curr Psychiatry Rep 22 (8): 37. June 2020. doi:10.1007/s11920-020-01164-1. PMID 32504127.
- ↑ 13.0 13.1 13.2 "Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders - 5". Curr Opin Psychiatry 25 (1): 52–58. January 2012. doi:10.1097/YCO.0b013e32834c3f19. PMID 22037092.
- ↑ 14.0 14.1 14.2 "Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms". J Pers Disord 23 (2): 156–174. April 2009. doi:10.1521/pedi.2009.23.2.156. PMID 19379093.
- ↑ "Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis". Psychiatry Res Commun 4 (3). September 2024. doi:10.1016/j.psycom.2024.100187. PMID 39309544.
- ↑ "Emerging evidence for the use of atypical antipsychotics in borderline personality disorder". Pharmacopsychiatry 38 (1): 20–23. January 2005. doi:10.1055/s-2005-837767. PMID 15706462.
- ↑ "Pharmacological Management of Borderline Personality Disorder and Common Comorbidities". CNS Drugs 37 (6): 489–497. June 2023. doi:10.1007/s40263-023-01015-6. PMID 37256484.
- ↑ 18.0 18.1 "Borderline Personality Disorder: A Review". JAMA 329 (8): 670–679. February 2023. doi:10.1001/jama.2023.0589. PMID 36853245.
- ↑ "Efficacy and tolerability of pharmacotherapies for borderline personality disorder". CNS Drugs 22 (8): 671–692. 2008. doi:10.2165/00023210-200822080-00005. PMID 18601305.
External links
 |  |
